Striverdi Respimat Approval History

  • FDA approved: Yes (First approved July 31st, 2014)
  • Brand name: Striverdi Respimat
  • Generic name: olodaterol
  • Company: Boehringer Ingelheim Pharmaceuticals Inc.
  • Treatment for: COPD

Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

FDA Approval History for Striverdi Respimat

DateArticle
Jul 31, 2014Approval FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease
Jan 30, 2013FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web5)